Latest Breaking News On - டேனியல் அல்கான் - Page 1 : comparemela.com
Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Synaptogenix Announces Regenerative Patent Award to Treat Alzheimer s Disease
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer s Disease Trial Update
- Data Safety Monitoring Board confirms Bryostatin-1 Safety
News provided by
Share this article
Share this article
NEW YORK, June 9, 2021 /PRNewswire/ Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced an update on its ongoing National Institutes of Health ( NIH ) sponsored Phase 2b clinical trial of Bryostatin-1 in patients suffering from moderately severe Alzheimer s disease ( AD ). To date, the Company has now dosed 58 of its target 100 patients. Seventeen sites continue to be live.
Additionally, the independent Data Safety Monitoring Board ( DSMB ) overseeing the trial convened to assess the safety of Bryostatin through an interim analysis and confirmed that 40 advanced AD patients have been dosed with Bryostatin without any significant safety issues.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Synaptogenix to Present at Sachs 4th Annual Neuroscience Innovation Forum
April 26, 2021 GMT
NEW YORK, April 26, 2021 /PRNewswire/ Synaptogenix, Inc. (OTC: SNPX) (“Synaptogenix” or the “Company”), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that Dr. Daniel Alkon, the Company’s President and Chief Scientific Officer, will present a “Spotlight Showcase” of Synaptogenix under the title “Regenerative Therapeutics” on Wednesday, April 28th at 12:40pm ET.
“Synaptogenix’s regenerative therapeutics for neurodegeneration is based on extensive pre-clinical data demonstrating the induction of new, fully mature synaptic connections that restore cognitive function in models of Alzheimer’s disease (“AD”), stroke, Fragile X syndrome, mental retardation and traumatic brain injury. Synaptogenix’s lead